Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer

National Cancer Center, Korea193 enrolled

Overview

The purpose of this study is to evaluate the role of routine Staging Laparoscopy in patients with potentially resectable pancreatobiliary cancer.

To evaluate the role of routine staging laparoscopy in patients with potentially resectable pancreatobiliary cancer. All analyses are performed using SAS version 9.1.3 for Windows (SAS institute, Cary, NC). Clinical and pathological variables will be analyzed using the χ2 test (or Fisher's exact test) and the Student's t test, depending on the normality of the distribution. P-values of \< 0.05 are considering statistically significant.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

193

Conditions

Pancreatic Cancer

Interventions

Staging LaparoscopyPROCEDURE

Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis. Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port.

Laparoscopic ultrasoundDEVICE

Eligibility

Sex: ALLMin age: 15 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) 2. No evidence of distant metastasis 3. aged 15-80 year old 4. performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale 5. adequate organ functions defined as indicated below 1. WBC 3000 \~ 12 000/mm3 2. \> Hb 8.0 g/dl 3. \> Plt 100 000/mm3 4. \< Cr 1.2 mg/dl 5. \> Ccr 60 ml/min/body Exclusion Criteria: 1. cystic neoplasm, neuroendocrine tumors 2. pregnant or breast-feeding women 3. previous upper abdominal surgery except laparoscopic cholecystectomy 4.Serious illness in medical condition 1. unstable angina or myocardial infarction within 6 months of the trial 2. unstable hypertension 3. congestive heart failure 4. severe respiratory disease requiring continuous oxygen therapy 5. liver failure 6. systemic administration of corticosteroids 7. severe mental disorder

Locations (1)

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

RECRUITING

Outcomes

Primary Outcomes

Probability of diagnosis of metastasis (frequency)

Time frame: baseline

Central Contacts

Sang Jae Park, MD

CONTACT

82-31-920-1640 spark@ncc.re.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.